Xu-Feng Zhang1,2, Eliza W Beal2, Jeffery Chakedis2, Yi Lv1, Fabio Bagante3, Luca Aldrighetti4, George A Poultsides5, Todd W Bauer6, Ryan C Fields7, Shishir Kumar Maithel8, Hugo P Marques9, Matthew Weiss3, Timothy M Pawlik10. 1. Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 2. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. 3. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA. 4. Department of Surgery, Scientific Institute San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. 5. Department of Surgery, Stanford University, Stanford, CA, USA. 6. Department of Surgery, University of Virginia, Charlottesville, VA, USA. 7. Department of Surgery, Washington University, School of Medicine, St Louis, MO, USA. 8. Department of Surgery, Emory University, Atlanta, Georgia. 9. Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal. 10. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. tim.pawlik@osumc.edu.
Abstract
BACKGROUND: Early tumor recurrence after curative resection typically indicates a poor prognosis. The objective of the current study was to investigate the risk factors, treatment, and prognosis of early recurrence of neuroendocrine tumor (NET) liver metastasis (NELM) after hepatic resection. METHODS: A total of 481 patients who underwent curative-intent resection for NELM were identified from a multi-institutional database. Data on clinicopathological characteristics, intraoperative details, and outcomes were documented. The optimal cutoff value to differentiate early and late recurrence was determined to be 3 years based on linear regression. RESULTS: With a median follow-up of 60 months, 223 (46.4%) patients developed a recurrence, including 158 (70.9%) early and 65 (29.1%) late recurrences. On multivariable analysis, pancreatic NET, primary tumor lymph node metastasis, and a microscopic positive surgical margin were independent risk factors for early intrahepatic recurrence. While recurrence patterns and treatments were comparable among patients with early and late recurrences, early recurrence was associated with worse disease-specific survival than late recurrences (10-year NELM-specific survival, 44.5 vs 75.8%, p < 0.001). Among the 34 (21.5%) patients who underwent curative treatment for early recurrence, post-recurrence disease-specific survival was better than non-curatively treated patients (10-year NELM-specific survival, 54.2 vs 26.3%, p = 0.028), yet similar to patients with late recurrences treated with curative intent (10-year NELM-specific survival, 54.2 vs 37.4%, p = 0.519). CONCLUSIONS: Early recurrence after surgery for NELM was associated with the pancreatic type, primary lymph node metastasis, and extrahepatic disease. Re-treatment with curative intent prolonged survival after recurrence, and therefore, operative intervention even for early recurrences of NELM should be considered.
BACKGROUND: Early tumor recurrence after curative resection typically indicates a poor prognosis. The objective of the current study was to investigate the risk factors, treatment, and prognosis of early recurrence of neuroendocrine tumor (NET) liver metastasis (NELM) after hepatic resection. METHODS: A total of 481 patients who underwent curative-intent resection for NELM were identified from a multi-institutional database. Data on clinicopathological characteristics, intraoperative details, and outcomes were documented. The optimal cutoff value to differentiate early and late recurrence was determined to be 3 years based on linear regression. RESULTS: With a median follow-up of 60 months, 223 (46.4%) patients developed a recurrence, including 158 (70.9%) early and 65 (29.1%) late recurrences. On multivariable analysis, pancreatic NET, primary tumor lymph node metastasis, and a microscopic positive surgical margin were independent risk factors for early intrahepatic recurrence. While recurrence patterns and treatments were comparable among patients with early and late recurrences, early recurrence was associated with worse disease-specific survival than late recurrences (10-year NELM-specific survival, 44.5 vs 75.8%, p < 0.001). Among the 34 (21.5%) patients who underwent curative treatment for early recurrence, post-recurrence disease-specific survival was better than non-curatively treated patients (10-year NELM-specific survival, 54.2 vs 26.3%, p = 0.028), yet similar to patients with late recurrences treated with curative intent (10-year NELM-specific survival, 54.2 vs 37.4%, p = 0.519). CONCLUSIONS: Early recurrence after surgery for NELM was associated with the pancreatic type, primary lymph node metastasis, and extrahepatic disease. Re-treatment with curative intent prolonged survival after recurrence, and therefore, operative intervention even for early recurrences of NELM should be considered.
Authors: J C Cusack; G G Giacco; K Cleary; B S Davidson; F Izzo; J Skibber; J Yen; S A Curley Journal: J Am Coll Surg Date: 1996-08 Impact factor: 6.113
Authors: Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: Gaya Spolverato; Fabio Bagante; Luca Aldrighetti; George A Poultsides; Todd W Bauer; Ryan C Fields; Shishir Kumar Maithel; Hugo P Marques; Matthew Weiss; Timothy M Pawlik Journal: J Surg Oncol Date: 2017-05-17 Impact factor: 3.454
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik Journal: J Am Coll Surg Date: 2012-10-11 Impact factor: 6.113
Authors: Luca Viganò; Lorenzo Capussotti; Réal Lapointe; Eduardo Barroso; Catherine Hubert; Felice Giuliante; Jan N M Ijzermans; Darius F Mirza; Dominique Elias; René Adam Journal: Ann Surg Oncol Date: 2013-12-18 Impact factor: 5.344
Authors: Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik Journal: World J Surg Date: 2018-09 Impact factor: 3.352
Authors: Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik Journal: Hepatobiliary Surg Nutr Date: 2020-08 Impact factor: 7.293
Authors: Ewald Jan Doornebal; Nicola Harris; Antonio Riva; Ravi Jagatia; Michail Pizanias; Andreas Prachalias; Krishna Menon; Melissa Preziosi; Ane Zamalloa; Rosa Miquel; Yoh Zen; Michael Robert Orford; Simon Eaton; Nigel Heaton; John Ramage; Elena Palma; Rajaventhan Srirajaskanthan; Shilpa Chokshi Journal: Front Endocrinol (Lausanne) Date: 2022-07-13 Impact factor: 6.055